felin
infecti
periton
viru
fipv
member
felin
coronaviru
famili
caus
fip
incur
fatal
cat
cyclosporin
csa
immunosuppress
agent
target
nuclear
factor
pathway
activ
tcell
nfat
bind
cellular
cyclophilin
cyp
dosedepend
inhibit
fipv
replic
vitro
immunosuppressor
pathway
bind
cellular
protein
fkbp
cyp
affect
fipv
replic
neither
cell
growth
viabil
chang
presenc
either
csa
factor
affect
nfat
pathway
cell
therefor
csa
seem
exert
inhibitori
effect
via
nfat
pathway
conclus
csa
inhibit
fipv
replic
vitro
studi
need
verifi
practic
valu
csa
antifipv
treatment
vivo
author
contribut
yt
carri
experi
particip
data
collect
analysi
prepar
manuscript
mi
st
carri
cell
cultur
viru
prepar
ys
perform
biochem
experi
ts
carri
luciferas
assay
author
read
approv
final
manuscript
coronavirus
singlestrand
rna
virus
gener
caus
respiratori
intestin
infect
sever
acut
respiratori
syndrom
sar
human
transmiss
gastroenter
tge
pig
felin
coronavirus
fcov
classifi
two
biotyp
compris
ubiquit
felin
enter
coronaviru
fecv
infecti
periton
viru
fipv
wide
accept
theori
vitro
fipv
aris
mutat
parent
fecv
gastrointestin
tract
infect
cat
system
spread
caus
fip
fatal
cat
although
mutat
site
fulli
understood
accessori
gene
candid
site
critic
mutat
respons
fip
approxim
purebr
cat
infect
felin
coronaviru
among
develop
classic
symptom
effus
wet
fip
noneffusivedri
form
fip
combin
two
mani
strategi
develop
cure
fip
interferon
inhibit
fipv
vitro
ineffect
vivo
variou
immunosuppress
glucocorticoid
cyclophosphamid
studi
although
drug
prolong
life
outcom
fipv
infect
remain
fatal
thu
effect
vaccin
therapeut
medicin
fipv
still
need
investig
report
immunosuppress
cyclosporin
csa
suppress
genom
replic
transcript
sever
virus
cyclophilin
cyp
cellular
factor
high
affin
csa
compris
famili
cellular
peptidylprolyl
cistran
isomeras
ppias
catalyz
cistran
interconvers
aminotermin
peptid
bond
prolin
residu
thu
facilit
chang
protein
conform
chaperon
protein
cyclosporin
block
enzymat
activ
cyp
lead
calcineurin
cn
nfat
pglycoprotein
pathway
capsid
protein
human
immunodefici
viru
type
possess
cyclophilin
cypa
bind
site
incorpor
virion
csainduc
reduct
cypa
inhibit
transport
reversetranscrib
viral
genom
nucleu
cyclophilin
b
cypb
anoth
target
csa
promot
hepat
c
viru
hcv
replic
regul
rnabind
abil
hcv
protein
addit
cypa
facilit
mous
cytomegaloviru
mcmv
replic
cypb
requir
infecti
entri
human
papillomaviru
type
show
csa
inhibit
intracellular
replic
fipv
genom
viral
protein
express
vitro
independ
nfat
pathway
feli
catu
whole
american
type
cultur
collect
va
usa
cell
maintain
dulbecco
modifi
eagl
medium
dmem
sigmaaldrich
tokyo
japan
supplement
fetal
bovin
serum
jrh
nissui
tokyo
japan
propag
fipv
strain
gift
dr
tsutomu
hodatsu
kitasato
univers
japan
cell
purifi
linear
sucros
gradient
ultracentrifug
inocul
cell
fipv
multipl
infect
moi
plaqueform
unit
pfu
per
cell
studi
effect
fipv
infect
adsorpt
h
medium
contain
viru
remov
cell
rins
three
time
phosphatebuff
salin
pb
incub
without
variou
concentr
csa
sigmaaldrich
cyclosporin
h
csh
cosmobio
tokyo
japan
sigmaaldrich
h
cell
process
photographi
cell
adsorb
fipv
rins
three
time
pb
overlaid
dmem
contain
fetal
bovin
serum
agaros
nippon
gene
toyama
japan
incub
cell
stain
giemsa
solut
plaqu
count
isol
nucleocapsid
n
gene
fipv
plasmid
provid
dr
peter
j
rottier
institut
biomembran
utrecht
univers
netherland
contain
fipv
genom
use
polymeras
chain
reaction
pcr
primer
first
amplif
product
first
amplif
purifi
electrophoresi
gel
extract
second
pcr
proceed
purifi
product
primer
contain
flagtag
sequenc
second
pcr
product
cut
nco
eco
ri
subclon
site
nco
eco
ri
ptriex
vector
novagen
takara
bio
kyoto
japan
express
flagtag
n
protein
cell
infect
moi
pfu
per
cell
incub
without
csa
csh
medium
remov
h
postinfect
rnaisoplu
takara
bio
ad
cell
rna
prepar
accord
manufactur
protocol
total
rna
ng
reversetranscrib
use
primescript
rtpcr
kit
perfect
real
time
takara
bio
viral
cdna
quantifi
realtim
pcr
use
forward
revers
primer
fipvn
gene
taqman
probe
famgttgca
reaction
mixtur
prepar
accord
manufactur
protocol
use
premix
extaq
takara
bio
sequenc
amplifi
use
sequenc
detect
system
appli
biosystem
tokyo
japan
follow
cycl
condit
initi
denatur
cycl
complementari
dna
fipvn
gene
clone
ptriex
vector
serial
dilut
provid
standard
fipv
gene
quantif
viral
rna
copi
number
normal
use
felin
gene
genbank
gene
deriv
cell
clone
pcr
amplif
use
follow
primer
amplifi
pcr
product
subclon
plasmid
biodynam
laboratori
inc
tokyo
japan
provid
standard
gene
quantifi
felin
gene
realtim
pcr
use
forward
revers
primer
gene
detect
gene
use
taqman
probe
tamracggactgctctatctgtc
luciferas
activ
quantifi
use
promega
tokyo
japan
vector
nfat
respons
assay
interferon
stimul
respons
determin
use
plasmid
pisretk
hrluc
f
provid
riken
bioresourc
center
tsukuba
japan
promot
promega
report
assay
proceed
use
dualluciferas
report
assay
system
promega
briefli
two
report
plasmid
cotransfect
cell
without
csa
assay
recombin
felin
pbl
biomed
laboratori
nj
usa
ad
concentr
unitsml
cultur
medium
evalu
respons
interferon
ifn
total
cell
lysat
prepar
report
lysi
buffer
provid
dualluciferas
report
assay
system
h
assay
luciferas
activ
quantifi
triplic
assay
use
lumat
berthold
technolog
tokyo
japan
cell
membran
disrupt
cell
lysi
buffer
mm
trishcl
ph
mm
ethylenediamin
tetraacet
acid
edta
nacl
includ
complet
mini
roch
diagnost
tokyo
japan
h
infect
cell
lysat
resolv
electrophoresi
bistri
gel
invitrogen
ca
usa
western
blot
onto
immobilonp
membran
millipor
tokyo
japan
nonspecif
protein
bind
block
nonfat
dri
milk
h
membran
incub
antifelin
coronaviru
nucleocapsid
n
antibodi
mybiosourc
ca
usa
sigmaaldrich
h
antigen
signal
visual
react
protein
membran
horseradish
peroxidaseconjug
antimous
igg
antibodi
promega
follow
enhanc
chemiluminesc
substrat
supersign
west
femto
maximum
sensit
substrat
thermo
scientif
tokyo
japan
accord
manufactur
protocol
assay
evalu
cytotox
use
cell
count
dojin
chemic
inc
wako
japan
accord
manufactur
direct
statist
signific
determin
use
student
test
data
analyz
signific
threshold
p
assum
valu
express
figur
mean
standard
deviat
sd
initi
assess
effect
csa
fipv
rna
replic
use
cytotox
assay
cyclosporin
concentr
cytotox
dose
affect
cell
viabil
figur
dosedepend
reduc
number
fipv
plaqu
figur
wherea
csa
slightli
cytotox
cyclosporin
block
enzymat
activ
cyp
lead
calcineurin
cn
nfat
pglycoprotein
pathway
therefor
assess
effect
variou
concentr
also
block
nfat
pathway
cell
viabil
confirm
csa
inhibit
fipv
pathway
cytopath
inhibitori
effect
significantli
differ
presenc
absenc
figur
cell
viabil
affect
figur
quantit
rtpcr
show
csa
dosedepend
suppress
fipv
rna
replic
wherea
exert
signific
inhibitori
effect
except
approxim
reduct
compar
p
figur
western
blot
show
csa
dosedepend
decreas
fipvn
protein
figur
examin
whether
suppress
effect
csa
fipv
replic
depend
inhibitori
nfat
pathway
pglycoprotein
pathway
incub
fipvinfect
cell
csh
specif
block
pglycoprotein
pathway
result
show
inhibit
occur
data
shown
determin
whether
action
csa
involv
activ
interferonstimul
gene
respons
cell
isreluciferas
report
plasmid
pisretk
hrluc
f
promot
plasmid
normalizationcontrol
plasmid
transfect
cell
cultur
felin
interferon
csa
result
dualluciferas
assay
show
none
factor
significantli
affect
luciferas
activ
h
transfect
result
indic
cell
unrespons
even
interferon
figur
consequ
action
csa
intracellular
fipv
replic
involv
activ
interferonstimul
gene
cell
moreov
evalu
effect
csa
calcineurinnfat
pathway
cell
nfat
luciferas
report
plasmid
normalizationcontrol
plasmid
transfect
cell
incub
csa
neither
csa
affect
nfat
luciferas
activ
cell
figur
find
show
csa
influenc
nfat
pathway
cell
inhibit
fipv
rna
replic
csa
independ
calcineurin
nfat
pathway
discov
csa
inhibit
intracellular
fipv
replic
vitro
result
qrtpcr
western
blot
show
viral
prolifer
strikingli
inhibit
csa
concentr
result
cell
viabil
assay
show
csa
slightli
cytotox
inhibitori
effect
concentr
therefor
consid
light
cytotox
contrast
immunosuppress
inhibit
fipv
replic
except
accord
qrtpcr
find
howev
inhibitori
effect
significantli
differ
western
blot
number
plaqu
significantli
differ
within
concentr
rang
find
might
relat
differ
analyt
detect
sensit
qrtpcr
western
blot
assay
cyclosporin
bind
cyclophilin
wherea
bind
cellular
fkbp
complex
independ
inhibit
phosphatas
activ
calcineurin
mediat
nfat
pathway
critic
express
cytokin
receptor
result
nfat
report
assay
indic
neither
csa
influenc
nfat
activ
cell
experiment
condit
thu
antivir
activ
fipv
involv
suppress
gene
respons
regul
nfat
instead
exert
distinct
mechan
independ
pfefferl
et
al
recent
describ
sarscoronaviru
overexpress
increas
signal
nfat
pathway
enhanc
induct
interleukin
data
somewhat
inconsist
find
discrep
might
explain
part
fact
experiment
system
includ
addit
pma
ionomycin
cultur
medium
knockdown
studi
nfat
gene
would
clarifi
role
fipv
prolifer
furthermor
stimul
isrepromot
activ
cell
condit
data
suggest
action
csa
intracellular
replic
fipv
independ
ifn
pathway
cell
line
might
respons
would
thu
use
isol
felin
coronaviru
cyclophilin
ppias
activ
contribut
matur
sever
protein
involv
cell
signal
mitochondri
function
atp
synthesi
molecular
chaperon
activ
rna
splice
stress
respons
gene
express
cholesterol
transport
regul
kinas
activ
surfac
plasmon
reson
technolog
bioinformat
tool
found
sar
coronaviru
n
protein
bind
cypa
therefor
n
protein
fipv
probabl
bind
cyp
protein
regul
viral
replic
role
cyp
viru
replic
inhibitori
effect
csa
hcv
sever
virus
studi
propos
mechan
inhibitori
effect
csa
mainli
involv
cypa
cypb
viru
replic
base
earlier
find
believ
interact
fipv
genom
like
viral
cyp
protein
play
critic
role
viral
replic
transcript
studi
requir
resolv
cyp
critic
viral
replic
viral
protein
requir
form
replic
complex
cyp
andor
cellular
protein
cat
clinic
diagnos
fip
rare
cure
although
sever
therapeut
strategi
attempt
cat
treat
prednisolon
phenylalanin
mustard
cyclophosphamid
gone
remiss
variou
immunosuppress
glucocorticoid
cyclophosphamid
may
prolong
life
alter
fatal
outcom
investig
use
ppias
dominantneg
assay
rna
interfer
method
warrant
clarifi
role
csa
ppias
fipv
replic
vitro
addit
whether
csa
could
use
fip
treatment
vivo
remain
determin
